Solexa Appoints Dr Simon Bennett As Business Development DirectorOctober 02, 2003New post reflects Solexa's progress towards commercialisation of its whole human genotyping system 1 October 2003, Little Chesterford, UKSolexa, the UK-based company developing systems that will allow rapid sequencing of individual genomes, has announced the appointment of Dr Simon Bennett as Business Development Director. Dr Bennett was previously Director of Business Development at Oxagen where he established and led genetics programmes in the areas of osteoporosis, endometriosis and women's health. Commenting on his appointment, Dr Bennett said, "Solexa is at an exciting stage of its development. Its single molecule array technology offers enormous potential in the emerging field of whole genome resequencing. I am looking forward to the challenge of helping to create the market for this truly enabling technology." At Oxagen Dr Bennett led a number of collaborations with the industry and academia and well as contributing to the developing ethics in the area of genetics in medicine. Prior to Oxagen he was a research fellow at the Wellcome Trust Centre for Human Genetics, University of Oxford, where he worked with Professor John Todd to help pioneer approaches to dissect complex diseases using genetics. Before that he was a research fellow at the Jodrell Laboratory at the Royal Botanic Gardens, Kew, where he helped to establish a molecular genetics laboratory. He has recently served on the committee of the Genetics Society of the UK and is the author of over 80 peer-reviewed scientific papers in genetics. Nick McCooke, Solexa's CEO, welcomed Dr Bennett to the Company, "Simon's appointment to the position of Business Development Director reflects the progress Solexa is making towards commercialisation of its technology and will be pivotal in ensuring we are in shape to attract partners and collaborators, and build on our existing relationships such as with the Sanger Institute. Our platform will radically improve the quality and quantity of information about individual genetic variation available for applications ranging from target discovery through to clinical implementation." | |||||||||||||||||||||
Science Research Departments
Earth Science Alternative Energy | Anthropology and Archaeology | Earthquakes and Volcanoes | Environment and Nature News | Global Warming | High-Energy and Particle Physics | Ozone Hole | Scientists Slow Light | Tsunami Space Science Astronomy and Space News | Black Holes | Chandra X-Ray Observatory | Extrasolar Planets | Hubble Telescope | International Space Station | Jupiter Galileo Mission | Jupiter Cassini Mission Flyby | Mars Exploration | Mars Odyssey 2001 | Mars Global Surveyor | Mars Polar Lander | Mars Climate Orbiter | Mars Pathfinder | Meteors and Asteroids | Mir Space Station | NEAR Asteroid Probe Mission | Pluto Planet Debate | Search for Extraterrestrial Life | Space Shuttle Program | Space Shuttle Mission: STS-102 | Space Weather Life Science Animal News | Biotechnology and Genetics | Brain Research | Human Cloning | Dinosaur and Fossil Discoveries | Endangered Species | Gene Therapy | Genetically Modified Food | Stem Cell Research | Whales and Whaling |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||